Natera, Inc. (NTRA)

Natera's stock price has been influenced by several factors. From March 28, 2025, to March 27, 2026, the share price increased by 26.89%, delivering a 31.7% return over the last year. Key events impacting the stock include strong Q4 2025 earnings, Q3 and Q2 2025 earnings, insider selling, macroeconomic headwinds, and product launches and data releases.

Natera expects typical seasonality in its women's health volumes and anticipates strong sequential growth from its Signatera and Prospera products. Overall, Natera has demonstrated robust demand for its services, with sales growing at an impressive 42.4% compounded annual growth rate over the last five years, and 46.3% over the last two years. Test volumes have also shown consistent increases.

Natera, Inc. is a biotechnology company specializing in cell-free DNA testing and advanced genetic analysis, headquartered in Austin, Texas. It operates in the healthcare sector, focusing on medical diagnostics and research. The company's technology integrates molecular biology, bioinformatics software, and AI to detect genetic information from blood samples. Natera generates revenue through Women's Health, Oncology, and Organ Health segments, with key products including Panorama NIPT, Signatera MRD Test, and Prospera Test, Horizon Carrier Screening, Anora Miscarriage (POC) Test, Spectrum Preimplantation Genetic Screening and Diagnosis Test, Vistara Single-Gene NIPT, and Empower Hereditary Cancer Test.

Natera is headquartered in the United States, where it conducts the majority of its laboratory operations. North America represents its largest revenue base. Internationally, Natera serves patients and healthcare providers in Europe, Asia-Pacific, and other global markets through partnerships, distributors, and select direct operations. The company continues to invest in expanding its global reach, particularly in regions with growing demand for non-invasive genetic testing. The U.S. accounts for over 90% of its total revenues.

Natera's brand reputation has been shaped by positive developments and legal challenges. The company's tests are validated by over 400 peer-reviewed publications, demonstrating high accuracy, and Natera aims to make personalized genetic testing and diagnostics part of the standard of care. Its Signatera test has become the most widely used MRD test in the U.S. However, Natera faced a false advertising lawsuit with Guardant Health and a NIPT false positive class action settlement, which impacted its reputation.

Natera, Inc. has a significant institutional ownership, with approximately 76.03% of the company's stock owned by institutional investors, 4.40% by insiders, and 19.57% by public companies and individual investors. Major institutional owners and shareholders include JPMorgan Chase & Co, Vanguard Group Inc, Price T Rowe Associates Inc /md/, BlackRock, Inc., Wellington Management Group Llp, Farallon Capital Management Llc, State Street Corp, Coatue Management Llc, Geode Capital Management, Llc, Aqr Capital Management Llc, and Fidelity. Co-founder Matthew Rabinowitz is the largest individual insider owner.